BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35008299)

  • 1. A Gene Signature Derived from the Loss of CDKN1A (p21) Is Associated with CMS4 Colorectal Cancer.
    Bueno-Fortes S; Muenzner JK; Berral-Gonzalez A; Hampel C; Lindner P; Berninger A; Huebner K; Kunze P; Bäuerle T; Erlenbach-Wuensch K; Sánchez-Santos JM; Hartmann A; De Las Rivas J; Schneider-Stock R
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
    Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
    BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration.
    Bastin J; Sroussi M; Nemazanyy I; Laurent-Puig P; Mouillet-Richard S; Djouadi F
    J Transl Med; 2023 Aug; 21(1):522. PubMed ID: 37533102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A partial epithelial-mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction.
    Pastorino GA; Sheraj I; Huebner K; Ferrero G; Kunze P; Hartmann A; Hampel C; Husnugil HH; Maiuthed A; Gebhart F; Schlattmann F; Gulec Taskiran AE; Oral G; Palmisano R; Pardini B; Naccarati A; Erlenbach-Wuensch K; Banerjee S; Schneider-Stock R
    J Pathol; 2024 Mar; 262(3):347-361. PubMed ID: 38235615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High SEMA4C expression promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal carcinoma.
    Hou Y; Wang W; Zeng Z; Gan W; Lv S; Li T; Yan Z; Zhang R; Yang M
    Aging (Albany NY); 2020 Nov; 12(21):21992-22018. PubMed ID: 33177246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.
    Källberg J; Harrison A; March V; Bērziņa S; Nemazanyy I; Kepp O; Kroemer G; Mouillet-Richard S; Laurent-Puig P; Taly V; Xiao W
    Cell Death Dis; 2023 May; 14(5):306. PubMed ID: 37142595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.
    Buikhuisen JY; Gomez Barila PM; Cameron K; Suijkerbuijk SJE; Lieftink C; di Franco S; Krotenberg Garcia A; Uceda Castro R; Lenos KJ; Nijman LE; Torang A; Longobardi C; de Jong JH; Dekker D; Stassi G; Vermeulen L; Beijersbergen RL; van Rheenen J; Huveneers S; Medema JP
    J Exp Clin Cancer Res; 2023 Mar; 42(1):56. PubMed ID: 36869386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of platelets in the consensus molecular subtypes of colorectal cancer.
    Lam M; Roszik J; Kanikarla-Marie P; Davis JS; Morris J; Kopetz S; Menter DG
    Cancer Metastasis Rev; 2017 Jun; 36(2):273-288. PubMed ID: 28681242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes.
    Wang K; Song K; Ma Z; Yao Y; Liu C; Yang J; Xiao H; Zhang J; Zhang Y; Zhao W
    Br J Cancer; 2020 Aug; 123(3):410-417. PubMed ID: 32435058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT3 Expression in Mesenchymal Colorectal Cancer Cells Drives Growth and Is Associated with Epithelial-Mesenchymal Transition.
    Buikhuisen JY; Gomez Barila PM; Torang A; Dekker D; de Jong JH; Cameron K; Vitale S; Stassi G; van Hooff SR; Castro MAA; Vermeulen L; Medema JP
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pre-existing population of ZEB2
    Francescangeli F; Contavalli P; De Angelis ML; Careccia S; Signore M; Haas TL; Salaris F; Baiocchi M; Boe A; Giuliani A; Tcheremenskaia O; Pagliuca A; Guardiola O; Minchiotti G; Colace L; Ciardi A; D'Andrea V; La Torre F; Medema J; De Maria R; Zeuner A
    J Exp Clin Cancer Res; 2020 Jan; 39(1):2. PubMed ID: 31910865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GRHL2 inhibits colorectal cancer progression and metastasis via oppressing epithelial-mesenchymal transition.
    Yang Z; Wu D; Chen Y; Min Z; Quan Y
    Cancer Biol Ther; 2019; 20(9):1195-1205. PubMed ID: 31063022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nidogen-1/NID1 Function and Regulation during Progression and Metastasis of Colorectal Cancer.
    Rokavec M; Jaeckel S; Hermeking H
    Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing heterogeneity along EMT and metabolic axes in colorectal cancer reveals underlying consensus molecular subtype-specific trends.
    Sehgal M; Ramu S; Vaz JM; Ganapathy YR; Muralidharan S; Venkatraghavan S; Jolly MK
    Transl Oncol; 2024 Feb; 40():101845. PubMed ID: 38029508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.
    De Smedt L; Palmans S; Andel D; Govaere O; Boeckx B; Smeets D; Galle E; Wouters J; Barras D; Suffiotti M; Dekervel J; Tousseyn T; De Hertogh G; Prenen H; Tejpar S; Lambrechts D; Sagaert X
    Br J Cancer; 2017 Jan; 116(1):58-65. PubMed ID: 27884016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients.
    Zhang Z; Zheng S; Lin Y; Sun J; Ding N; Chen J; Zhong J; Shi L; Xue M
    BMC Cancer; 2020 Nov; 20(1):1135. PubMed ID: 33228590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor of growth 4 suppresses colorectal cancer growth and invasion by inducing G1 arrest, inhibiting tumor angiogenesis and reversing epithelial-mesenchymal transition.
    Qu H; Yin H; Yan S; Tao M; Xie Y; Chen W
    Oncol Rep; 2016 May; 35(5):2927-35. PubMed ID: 26936485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Transcription Factor Signature Can Identify the CMS4 Subtype and Stratify the Prognostic Risk of Colorectal Cancer.
    Zhong ME; Huang ZP; Wang X; Cai D; Li CH; Gao F; Wu XJ; Wang W
    Front Oncol; 2022; 12():902974. PubMed ID: 35847938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway.
    Chen J; Yuan W; Wu L; Tang Q; Xia Q; Ji J; Liu Z; Ma Z; Zhou Z; Cheng Y; Shu X
    Oncotarget; 2017 Feb; 8(6):9961-9973. PubMed ID: 28035069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway.
    Xu C; Sun L; Jiang C; Zhou H; Gu L; Liu Y; Xu Q
    Biomed Pharmacother; 2017 Jul; 91():1167-1177. PubMed ID: 28531945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.